High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology

다국어 초록 (Multilingual Abstract)

Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts:• Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia.
• Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method.
• The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years.
• Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.

참고문헌 (Reference)

1 zur Hausen H, "Viruses in the etiology of human genital cancer" 30 : 170-186, 1984

2 Huh WK, "Use of primary high-risk human papillomavirus testing for cervical cancer screening : interim clinical guidance" 136 : 178-182, 2015

3 Huh WK, "Use of primary high-risk human papillomavirus testing for cervical cancer screening : interim clinical guidance" 125 : 330-337, 2015

4 Rizzo AE, "Update on primary HPV screening for cervical cancer prevention" 42 : 507-520, 2018

5 Arbyn M, "Trends of cervical cancer mortality in the member states of the European Union" 45 : 2640-2648, 2009

6 Choi JW, "The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital" 124 : 144-152, 2016

7 Ghittoni R, "The biological properties of E6 and E7 oncoproteins from human papillomaviruses" 40 : 1-13, 2010

8 민경진, "The Korean guideline for cervical cancer screening" 대한부인종양학회 26 (26): 232-239, 2015

9 Baker TS, "Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction" 60 : 1445-1456, 1991

10 Basu P, "Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report" 142 : 44-56, 2018

11 American Society for Colposcopy and Cervical Pathology, "Screening guidelines" ASCCP

12 Melnikow J, "Screening for cervical cancer with high-risk human papillomavirus testing : updated evidence report and systematic review for the US Preventive Services Task Force" 320 : 687-705, 2018

13 Kim JJ, "Screening for cervical cancer in primary care : a decision analysis for the US Preventive Services Task Force" 320 : 706-714, 2018

14 US Preventive Services Task Force, "Screening for cervical cancer : US Preventive Services Task Force recommendation statement" 320 : 674-686, 2018

15 Dijkstra MG, "Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus : 14 year follow-up of population based randomised cohort in the Netherlands" 355 : i4924-, 2016

16 Moscicki AB, "Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females" 285 : 2995-3002, 2001

17 Ronco G, "Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test" 100 : 492-501, 2008

18 Dickinson J, "Recommendations on screening for cervical cancer" 185 : 35-45, 2013

19 Gage JC, "Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test" 106 : dju153-, 2014

20 Wright TC, "Primary cervical cancer screening with human papillomavirus : end of study results from the ATHENA study using HPV as the first-line screening test" 136 : 189-197, 2015

21 O'Brien PM, "Papillomaviruses : a correlation between immune evasion and oncogenicity?" 11 : 300-305, 2003

22 Bulkmans NW, "POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening : design, methods and baseline data of 44, 102 women" 110 : 94-101, 2004

23 Cuzick J, "Overview of the European and North American studies on HPV testing in primary cervical cancer screening" 119 : 1095-1101, 2006

24 Department of Health (AU), "National Cervical Screening Program" Department of Health

25 The Society for Colposcopy and Cervical Pathology of Singapore, "Management guidelines for cervical screening & preinvasive disease of the cervix" The Society for Colposcopy and Cervical Pathology of Singapore

26 Wingo PA, "Long-term trends in cancer mortality in the United States, 1930–1998" 97 : 3133-3275, 2003

27 Stoler MH, "Interobserver reproducibility of cervical cytologic and histologic interpretations : realistic estimates from the ASCUS-LSIL Triage Study" 285 : 1500-1505, 2001

28 Wright TC Jr, "Interlaboratory variation in the performance of liquid-based cytology : insights from the ATHENA trial" 134 : 1835-1843, 2014

29 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015" 대한부인종양학회 30 (30): 1-8, 2019

30 Rijkaart DC, "Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer : final results of the POBASCAM randomised controlled trial" 13 : 78-88, 2012

31 Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide" 189 : 12-19, 1999

32 de Sanjose S, "Human papillomavirus genotype attribution in invasive cervical cancer : a retrospective cross-sectional worldwide study" 11 : 1048-1056, 2010

33 Naucler P, "Human papillomavirus and Papanicolaou tests to screen for cervical cancer" 357 : 1589-1597, 2007

34 Mayrand MH, "Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer" 357 : 1579-1588, 2007

35 Kitchener HC, "HPV testing in combination with liquid-based cytology in primary cervical screening(ARTISTIC) : a randomised controlled trial" 10 : 672-682, 2009

36 Ogilvie GS, "HPV for cervical cancer screening(HPV FOCAL) : Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer" 140 : 440-448, 2017

37 Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries" 68 : 394-424, 2018

38 Winer RL, "Genital human papillomavirus infection : incidence and risk factors in a cohort of female university students" 157 : 218-226, 2003

39 Ronco G, "Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia : a randomised controlled trial" 11 : 249-257, 2010

40 Ronco G, "Efficacy of HPV-based screening for prevention of invasive cervical cancer : follow-up of four European randomised controlled trials" 383 : 524-532, 2014

41 Ogilvie GS, "Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months : The HPV FOCAL randomized clinical trial" 320 : 43-52, 2018

42 Leinonen MK, "Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing : prospective randomised trial in Finland" 345 : e7789-, 2012

43 Jemal A, "Declining death rates reflect progress against cancer" 5 : e9584-, 2010

44 Solomon D, "Comparison of three management strategies for patients with atypical squamous cells of undetermined significance : baseline results from a randomized trial" 93 : 293-299, 2001

45 Cook DA, "Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial" 15 : 968-, 2015

46 Public Health England, "Cervical screening: implementation guide for primary HPV screening" Public Health England

47 Canfell K, "Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination : Results of the Compass pilot randomised trial" 14 : e1002388-, 2017

48 Benard VB, "Cervical carcinoma rates among young females in the United States" 120 : 1117-1123, 2012

49 Chrysostomou AC, "Cervical cancer screening programs in Europe : the transition towards HPV vaccination and population-based HPV testing" 10 : E729-, 2018

50 National Institute for Public Health and the Environment (NL), "Cervical cancer screening programme" National Institute for Public Health and the Environment

51 Bujan Rivera J, "Cervical cancer screening in Germany" 61 : 1528-1535, 2018

52 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015" 대한암학회 50 (50): 303-316, 2018

53 Kitchener HC, "ARTISTIC : a randomised trial of human papillomavirus(HPV)testing in primary cervical screening" 13 : 1-150, 2009

54 Bouvard V, "A review of human carcinogens--Part B : biological agents" 10 : 321-322, 2009

55 Ogilvie GS, "A randomized controlled trial of Human Papillomavirus(HPV)testing for cervical cancer screening : trial design and preliminary results(HPV FOCAL Trial)" 10 : 111-, 2010

56 Boshart M, "A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer" 3 : 1151-1157, 1984

57 Massad LS, "2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors" 17 : S1-27, 2013

58 Wright TC Jr, "2001 Consensus Guidelines for the management of women with cervical cytological abnormalities" 287 : 2120-2129, 2002